Moxifloxacin retains antimycobacterial activity in the presence of gyra mutations

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2912-2915

  McGrath, Marieta ^a   Van Pittius, Nico C Gey ^a   Sirgel, FreDerick A ^a   Van Helden, Paul D ^a   Warren, Robin M ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; OFLOXACIN; BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMYCOBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CODON; DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS;

EID: 84898658016     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02583-13     Document Type: Article

References (22)

1. World Health Organization. 2011. Guidelines for the programmatic management of drug-resistant tuberculosis- 2011 update. WHO Press, Geneva, Switzerland.
2. World Health Organization. 2010. Treatment of tuberculosis: guidelines, 4th ed. WHO Press, Geneva, Switzerland.
3. Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T. 2010. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J. Antimicrob. Chemother. 65:946-952. http://dx.doi.org/10.1093/jac/dkq091.
4. World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs.WHOPress, Geneva, Switzerland.
5. Kam KM, Yip CW, Cheung TL, Tang HS, Leung OC, Chan MY. 2006. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb. Drug Resist. 12:7-11. http://dx.doi.org/10.1089/mdr. 2006.12.7.
6. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. 2012. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 67:1088-1093. http://dx.doi.org/10.1093/jac/dks033.
7. Cheng AFB, Yew WW, Chan EWC, Chin ML, Hui MMM, Chan RCY. 2004. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 48:596-601. http://dx.doi.org/10.1128/AAC.48.2. 596-601.2004.
8. Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, Da Silva PA. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53:4498-4500. http://dx.doi.org/10.1128/AAC.00287-09.
9. Nosova EY, Bukatina AA, Isaeva YD, Makarova MV, Galkina KY, Moroz AM. 2013. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J. Med. Microbiol. 62:108-113. http://dx.doi.org/10.1099/jmm. 0.046821-0.
10. Poissy J, Aubry A, Fernandez C, Lott M-C, Chauffour A, Jarlier V, Farinotti R, Veziris N. 2010. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob. Agents Chemother. 54:4765-4771. http://dx.doi.org/10.1128/AAC.00968- 10.
11. World Health Organization. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis- emergency update 2008. WHO Press, Geneva, Switzerland.
12. Clayden P, Collins S, Daniels C, Geffen N, Harrington M, Jefferys R, Jervis C, Kaplan K, Lessem E, Swan T. 2012. 2012 pipeline report: HIV, hepatitis C virus (HCV), and tuberculosis (TB) drugs, diagnostics, vaccines, and preventive technologies in development. i-BASE/Treatment Action Group, New York, NY.
13. Conde MB, Efron A, Loredo C, De Souza GRM, Graça NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183- 1189. http://dx.doi.org/10.1016/ S0140-6736(09)60333-0.
14. Almeida D, Nuermberger E, Tyagi S, Bishai WR, Grosset J. 2007. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob. Agents Chemother. 51: 4261-4266. http://dx.doi.org/10.1128/AAC.01123-07.
15. Manika K, Chatzika K, Zarogoulidis K, Kioumis I. 2012. Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring? Eur. Respir. J. 40:1051-1053. http://dx.doi.org/10.1183/09031936. 00202411.
16. Morlock GP, Plikaytis BB, Crawford JT. 2000. Characterization of spontaneous, in vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv. Antimicrob. Agents Chemother. 44:3298- 3301. http://dx.doi.org/10.1128/AAC.44.12.3298-3301.2000.
17. Ginsburg AS, Sun R, Calamita H, Scott CP, Bishai WR, Grosset JH. 2005. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob. Agents Chemother. 49:3977-3979. http://dx.doi.org/10.1128/AAC.49.9.3977-3979.2005.
18. Sekiguchi J, Disratthakit A, Maeda S, Doi N. 2011. Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone. Antimicrob. Agents Chemother. 55:3958-3960. http://dx.doi.org/10. 1128/AAC.00417-10.
19. Van der Heijden YF, Maruri F, Blackman A, Mitchel E, Bian A, Shintani AK, Eden S, Warkentin JV, Sterling TR. 2013. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after prediagnosis ex- posure to older-versus newer-generation fluoroquinolones. Int. J. Antimicrob. Agents 42:232-237. http://dx.doi.org/10.1016/j.ijantimicag.2013.04.027.
20. Hall BM, Ma C-X, Liang P, Singh KK. 2009. Fluctuation analysis CalculatOR: a web tool for the determination of mutation rate using Luria- Delbruck fluctuation analysis. Bioinformatics 25:1564-1565. http://dx.doi.org/ 10.1093/bioinformatics/btp253.
21. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. 2010. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-Analysis. Clin. Infect. Dis. 51:6-14. http://dx.doi.org/10. 1086/653115.
22. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J. Antimicrob. Chemother. 67:819-831. http://dx.doi.org/10. 1093/jac/dkr566.